Synairgen announced that it will present data from the Phase 3 SPRINTER trial of its SNG001 nebulized interferon-beta-1a in hospitalized COVID-19 patients at an upcoming meeting showing that treatment with SNG001 reduced symptoms of long COVID at 60 and 90 days post treatment compared to placebo. According to the data provided, patients treated with SNG001 had a 28.3% lower relative risk of dyspnoea; a 35.4% lower relative risk of fatigue; and a 61.4% lower relative risk of loss of smell and/or taste compared to patients who received an inhaled placebo.
The SPRINTER trial, which was initiated in January 2021 and was completed in February 2022, did not meet its primary or secondary endpoints. A Phase 2 trial completed in June 2020, early in the pandemic, demonstrated significant benefits for hospitalized patients treated with SNG001 compared to placebo.
Synairgen CEO Richard Marsden said, “The announcement of this data from our 60 and 90-day follow-up in patients who participated in the SPRINTER trial adds to our rationale of supporting further development and investigation of SNG001 as a broad-spectrum antiviral for severe respiratory infections. We look forward to presenting the results at IDWeek in October.”
Read the Synairgen press release.
